Combo Trials With Merck, Bristol Highlight Lilly’s Focus On Oncology Going Forward

Combo trials with Opdivo and Keytruda may help Lilly accelerate its move into cancer immunotherapy. Heading out of its patent cliff, the pharma is focused mainly on cancer, diabetes and neurology.